SCHEMBL16611339

SCHEMBL16611339

COc1nccc2c1c(-c1ccc(N3CCOCC3)cc1)nn2C1CCCCC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.39
ALDH1A1 P00352 5/20 0.38
CYP1A2 P05177 5/20 0.38
CASP1 P29466 5/20 0.38
CASP7 P55210 5/20 0.38
HSD17B10 Q99714 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
GSK3B P49841 1/20 0.37
USP2 O75604 3/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
SYK P43405 1/20 0.36
HIF1A Q16665 2/20 0.35
MAPK1 P28482 2/20 0.35
ALOX5 P09917 2/20 0.35
ALOX15 P16050 1/20 0.35
RECQL P46063 1/20 0.35
PDE3B Q13370 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610876 0.83 SLC18A3 (0.41) LRRK2ALDH1A1CYP1A2CASP1CASP7
SCHEMBL16611010 0.82 LRRK2 (0.38) LRRK2ALDH1A1CYP1A2CASP1CASP7
SCHEMBL16610837 0.78 LRRK2 (0.44) LRRK2ALDH1A1CYP1A2CASP1CASP7
SCHEMBL16610962 0.74 MAP4K1 (0.41) LRRK2ALDH1A1CYP1A2CASP1CASP7
SCHEMBL16610911 0.72 TSHR (0.41) LRRK2ALDH1A1CYP1A2CASP1CASP7
SCHEMBL16611322 0.70 TBK1 (0.43) LRRK2GSK3BPRKDCKCNH2
SCHEMBL16611225 0.69 TGFBR1 (0.42) LRRK2PRKDC
SCHEMBL16611763 0.69 CCNA2 (0.43) LRRK2ALDH1A1GSK3BMAPTPRKDC
SCHEMBL16610949 0.69 LRRK2 (0.74) LRRK2
SCHEMBL16610902 0.68 EGFR (0.46) PRKDCKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LRRK2 1393/4885ALDH1A1 3511/4885CYP1A2 3322/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LRRK2 1393/4885ALDH1A1 3511/4885CYP1A2 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.